Back to top

Analyst Blog

KaloBios Pharmaceuticals, Inc. (KBIO) received a Notice of Allowance for a composition of matter patent covering certain antibodies targeting EphA3, which includes its oncology candidate KB004. The Notice of Allowance received from the U.S. Patent and Trademark Office validates the uniqueness of KB004 and the company’s Humaneered technology incorporated into it.

KaloBios is currently conducting a phase I study on its anti-EphA3 mAb, KB004, for the treatment of hematologic malignancies. KaloBios plans to start the phase II study evaluating the efficacy of KB004 in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) by year end. Initial results from these studies are expected in the second quarter of 2015.

We are encouraged by KaloBios’ pipeline progress. Besides KB004, the company also has another interesting candidate in its pipeline - KB001-A, a second generation, anti-TTSS antibody. The candidate is currently in a phase II study for the treatment of chronic pseudomonas aeruginosa (Pa) infections in cystic fibrosis (CF) patients.

Enrollment is expected to complete in mid-2014 with top-line results due in the fourth quarter of 2014. KaloBios enjoys  orphan drug status for KB001-A in the EU and U.S. The Food and Drug Administration (FDA) granted Fast Track Designation to KB001-A, for the treatment of Pa in the intensive care setting.

Meanwhile, KaloBios has completed enrollment of 160 patients in a phase II study on another candidate, KB003. KB003 is being studied for the treatment of severe asthma. KaloBios anticipates top-line results in the first quarter of 2014.

KaloBios carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Aeterna Zentaris Inc. , Actelion Ltd. (ALIOF) and Jazz Pharmaceuticals plc (JAZZ - Analyst Report), each carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%